Low Risk of Thromboembolic Events After Routine Administration of Tranexamic Acid in Hip and Knee Arthroplasty

2017 ◽  
Vol 32 (4) ◽  
pp. 1298-1303 ◽  
Author(s):  
Rune V. Madsen ◽  
Christian S. Nielsen ◽  
Thomas Kallemose ◽  
Henrik Husted ◽  
Anders Troelsen
2012 ◽  
Vol 471 (1) ◽  
pp. 150-154 ◽  
Author(s):  
Blake P. Gillette ◽  
Lori J. DeSimone ◽  
Robert T. Trousdale ◽  
Mark W. Pagnano ◽  
Rafael J. Sierra

Author(s):  
Nathan H. Varady ◽  
Antonia F. Chen ◽  
Nicholas J. Drayer ◽  
John Ready ◽  
Santiago A. Lozano‐Calderon ◽  
...  

2015 ◽  
Vol 23 (12) ◽  
pp. 732-740 ◽  
Author(s):  
J. Stuart Melvin ◽  
Louis S. Stryker ◽  
Rafael J. Sierra

2021 ◽  
Vol 29 (4) ◽  
pp. 184-188
Author(s):  
OTÁVIO MONTOVANELLI MONTEIRO ◽  
RODRIGO TURRA PERRONE ◽  
FABRÍCIO NASCIMENTO ALMEIDA ◽  
CID PEREIRA DE MOURA JUNIOR ◽  
SAULO GOMES DE OLIVEIRA ◽  
...  

ABSTRACT Objective: To compare the use of intravenous and topical tranexamic acid (TXA) in unilateral primary total knee arthroplasty (TKA) in relation to blood loss and complications inherent to the medication. Method: Three groups with 14 patients each were constituted, and all of them were operated using the same surgical technique. In Group 1, usual measures for bleeding control were performed. Group 2 patients received TXA topically on the joint surface. In Group 3, intravenous TXA was used. Hemoglobin (HB), hematocrit (HTC), platelets (PLAT), prothrombin time, activated partial thromboplastin time and volume of blood drained observed 24 hours after arthroplasty were compared to the values of tests found before surgery. Results: There was a decrease in the concentration of HB, HTC and PLAT in all groups in relation to the preoperative, however without significant difference. Group 3 had a lower mean volume of drained blood than the other groups, with statistical significance. No adverse effects or thromboembolic events were observed in the groups that received TXA. Conclusion: This study showed superiority in the use of intravenous TXA in decreasing the volume of bleeding, without increasing the risk of thromboembolic events. Level of Evidence I, High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals.


2014 ◽  
Vol 29 (4) ◽  
pp. 681-684 ◽  
Author(s):  
Julian Gilbody ◽  
Herman S. Dhotar ◽  
Anthony V. Perruccio ◽  
J. Roderick Davey

2020 ◽  
Vol 8 (8) ◽  
Author(s):  
Jennifer Remington ◽  
Rachana Patel ◽  
William Stanfield ◽  
Karen Kier ◽  
Amber Baehr

Sign in / Sign up

Export Citation Format

Share Document